Professional
Added to YB: 2025-12-11
Pitch date: 2025-12-09
GXI.DE [bearish]
Gerresheimer AG
-12.48%
current return
Author Info
Morpheus Research was founded in 2025 by a team of financial analysts dedicated to exposing fraud and corporate misconduct in financial markets.We publish deep-dive investigative research on companies that we feel are fundamentally misunderstood by the market. While our research may lead to uncomfortable conclusions, we strive only to offer the truth. Sign up for the newsletter.
Company Info
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally.
Market Cap
EUR 856.6M
Pitch Price
EUR 25.00
Price Target
N/A
Dividend
0.16%
EV/EBITDA
7.56
P/E
36.68
EV/Sales
1.35
Sector
Life Sciences Tools and Services
Category
turnaround
Gerresheimer AG – A Conflicted Acquisition, Flailing Divestiture & Accounting Games Coming To Roost As Key Weight-Loss Driver At Risk
GXI.DE: German pharma packaging co down 80% from peak. Key CagriSema dual-chamber syringe contract at risk as Novo delays filing due to 'supply chain readiness' & quality issues. Single-chamber alternatives emerging. €800M Bormioli acquisition at 10x EBITDA faces €51M 2024 losses, channel stuffing, aging assets. Net debt 4.15x EBITDA covenant. Molded glass divestiture struggling. BaFin investigating bill-and-hold practices. Multiple aggressive accounting tactics inflating metrics.
Read full article (10 min)